BrioVAD System
Phase 1- Indications
- Advanced heart failure
Company intelligence / Profile preview
The BrioVAD® System, a next-generation left ventricular assist system featuring a fully magnetically suspended blood pump and patient-centric design, has entered clinical evaluation in the U.S. through the INNOVATE trial. Over 350 patients outside the U.S. have been treated with systems incorporating this technology. The INNOVATE trial aims to assess safety and effectiveness compared to standard-of-care LVADs for advanced refractory left ventricular heart failure. The system remains investigational and not yet FDA approved.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BrioHealth Solutions.